Obatoclax reduces cell viability of acute myeloid leukemia cell lines independently of their sensitivity to venetoclax
Keli Lima,
Hugo Passos Vicari,
Jorge Antonio Elias Godoy Carlos,
Jean Carlos Lipreri da Silva,
Lorena Lobo de Figueiredo-Pontes,
Eduardo Magalhães Rego,
João Agostinho Machado-Neto
Affiliations
Keli Lima
Institute of Biomedical Sciences, Universidade de Sao Paulo, Sao Paulo, SP, Brazil; Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil
Hugo Passos Vicari
Institute of Biomedical Sciences, Universidade de Sao Paulo, Sao Paulo, SP, Brazil
Jorge Antonio Elias Godoy Carlos
Institute of Biomedical Sciences, Universidade de Sao Paulo, Sao Paulo, SP, Brazil
Jean Carlos Lipreri da Silva
Institute of Biomedical Sciences, Universidade de Sao Paulo, Sao Paulo, SP, Brazil
Lorena Lobo de Figueiredo-Pontes
Hematology and Clinical Oncology, Ribeirão Preto Medical School, Universidade de Sao Paulo, Ribeirao Preto, Sao Paulo, SP, Brazil
Eduardo Magalhães Rego
Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil
João Agostinho Machado-Neto
Institute of Biomedical Sciences, Universidade de Sao Paulo, Sao Paulo, SP, Brazil; Corresponding author at: Department of Pharmacology, Institute of Biomedical Sciences, Universidade de Sao Paulo, Av. Prof. Lineu Prestes, 1524, CEP 05508-900 São Paulo, SP, Brazil.
